Dr.  Xavier Frapaise, is the CEO at EUxerel, a company supporting the European medical activities of US-based biotechs.

In 2009, Dr. Frapaise joined Optimer Pharmaceuticals as Chief Scientific Officer with over thirty years of international drug development, strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer and Abbott.  Prior to joining Optimer, Dr. Frapaise was the President and CEO of Asphelia Pharmaceuticals and served as the Chief Medical Officer at Ocera Therapeutics Inc. From 2001 to 2006 he was the Corporate Officer and Vice President of R&D at TAP Pharmaceuticals.  Dr.  Frapaise’s career also included positions such as Vice President Scientific Affairs at Abbott International Division, head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, Vice President of R&D at Delagrange, head of Anti-thrombotics Strategic Marketing at Sanofi, and Medical Director at Choay.  His development and regulatory experience include anti-infectives, gastroenterology,anti-thrombotics, diabetes, and cardio-vascular products.

Dr. Frapaise holds an M.D. degree from the Faculte de Medecine Rene Descartes in Paris, France, and is an INSEAD alumnus. He holds an academic position at the Loyola University Medical Center (Thrombosis Research Center) in Chicago.